ResearchPUBMEDMar 26
Tracing the path of non-industry-driven medicine development for rare diseases through regulatory interactions at the European Medicines Agency.
Researchers studied how medicines for rare diseases are developed by non-industry groups like universities and charities, compared to pharmaceutical companies. Between 2000 and 2022, only about 7% of rare disease medicine projects came from these non-industry organizations. While these groups got help from regulators at similar rates as companies, very few of their medicines actually made it to patients—only six succeeded, and all had to partner with pharmaceutical companies to finish the job.
WHY IT MATTERSThis research shows that academic and charity-led rare disease drug projects face significant barriers to reaching patients, suggesting that funding and regulatory support for non-industry developers could unlock more treatment options for rare diseases that pharmaceutical companies might overlook.
ℹ Good to knowRead →